Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LIPINTOECTION

Financiado

Cerrado

Lipoproteins and angiogenesis A new look at an old problem

Cardiovascular diseases (CVDs) are the leading cause of death throughout the world. Elevated Low Density Lipoprotein (LDL) is a well-known cardiovascular risk factor and endothelial (ECs)-lipoprotein (LIPs) interactions underlie t... ver más

30/11/2018

WEIZMANN

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-11-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

WEIZMANN

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

COMPLEMENT AND LDL COMPLEMENT AND ATHEROSCLEROSIS MOLECULAR MECHANISM OF C1 AC... 172K€ Cerrado

SAF2012-40208 EFECTOS FUNCIONALES Y MOLECULARES DE DISTINTAS FORMAS DE HDL... 94K€ Cerrado

PAELLA Platelet Endothelial Aggregation Receptor 1 213K€ Cerrado

PROVASC Cell specific vascular protection by CXCL12 CXCR4 2M€ Cerrado

S1PWSSECpermeability Correlation Between Numerical Estimation of In Vivo Local Sp... 210K€ Cerrado

SAF2012-40127 MECANISMOS CELULARES Y MOLECULARES QUE INVOLUCRAN AL RECEPTO... 164K€ Cerrado

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiovascular diseases (CVDs) are the leading cause of death throughout the world. Elevated Low Density Lipoprotein (LDL) is a well-known cardiovascular risk factor and endothelial (ECs)-lipoprotein (LIPs) interactions underlie the initiation and progression of atherogenesis, thrombosis and other CVDs. The endothelium is a monolayer of cells that segregates the vascular contents from adjacent tissues. In spite of being continually exposed to LIPs, ECs were long thought of as inert barriers, through which lipids are exchanged between plasma and surrounding tissues. In contrast to this view, recent work from my laboratory has uncovered a deleterious role of ApoB-LIPs as direct inhibitors of angiogenesis in the developing embryo. These findings present only the tip of the iceberg, and the underlying cellular and molecular mechanisms are largely unknown. In this proposal, we will tackle this question by undertaking three independent but complementary approaches, aimed at characterizing LIP-EC interactions at a different level: cellular, molecular or pathological. We will explore these facets in zebrafish and mammals, utilizing live imaging, sophisticated lipidomic and biochemical analyses, as well as tumor xenografts and genetic mutants. An important and unique aspect of our approach is the focus on in vivo dynamics, in contrast to the extensive body of literature on LIP effects on cultured ECs. When completed this proposal will have shed light on a little explored, but critical aspect in the etiology of CVDs. Furthermore it will provide answers to important unresolved questions: What are the signaling pathways activated in ECs upon LIP binding? How are LIPs transported within ECs? Does ApoB possess additional functions beyond that of cholesterol carrier? Can high LIPs levels inhibit tumor angiogenesis and metastasis? In a broader sense, a deeper understanding of the effects of LIPs on ECs will be valuable for identifying new targets for therapeutic intervention.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores